Pluristem Moves Forward in the Orthopedic Area with the Support of Key Opinion Leaders
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, today announced it has enhanced its activity in the orthopedic indications for its PLacental eXpanded (PLX) cell therapies. In January, Pluristem announced positive results from its Phase I/II clinical trial for the treatment of injured gluteal muscle after total hip arthroplasty (THA) . "This is a great result for a long path from a first idea to such a success in a first-in-men study in orthopedics with an off-the-shelf product...
View full press release